Barclays Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation

Fintel reports that on July 12, 2024, Barclays initiated coverage of Revolution Medicines (NasdaqGS:RVMD) with a Overweight recommendation. https://www.nasdaq.com/articles/barclays-initiates-coverage-revolution-medicines-rvmd-overweight-recommendation